Jupiter Neurosciences (JUNS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $2.90, -7.48% vs the prior close of $3.14.
- Volume 13.92K shares, 0.0x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
JUNS slides 7.5% to $2.90, 3 down days in a row. Closed at $2.90, -7.48% vs the prior close of $3.14. Day range $2.88–$3.10, opened at $3.09.
JUNS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — JUNS slides 7.5% to $2.90, 3 down days in a row
- Closed at $2.90, -7.48% vs the prior close of $3.14. Day range $2.88–$3.10, opened at $3.09.
- Volume was 13.92K shares, 0.0x its 50-day average of 1.14M — lighter than usual.
- Price is -20.7% vs its 50-day average ($3.66) and -88.0% vs its 200-day average ($24.19).
- 52-week range $2.25–$135.75; today's close sits at 0% of that range, 97.9% below the 52-week high.
- That makes 3 straight losses.
Oct 15, 2026 — JUNS dips 1.6% to $3.14
- Closed at $3.14, -1.57% vs the prior close of $3.19. Day range $3.03–$3.27, opened at $3.16.
- Volume was 19.80K shares, 0.0x its 50-day average of 1.14M — lighter than usual.
- Price is -15.5% vs its 50-day average ($3.72) and -87.2% vs its 200-day average ($24.58).
- 52-week range $2.25–$135.75; today's close sits at 1% of that range, 97.7% below the 52-week high.
Oct 14, 2026 — JUNS slides 5.1% to $3.19
- Closed at $3.19, -5.06% vs the prior close of $3.36. Day range $3.07–$3.43, opened at $3.30.
- Volume was 20.10K shares, 0.0x its 50-day average of 1.14M — lighter than usual.
- Price is -15.3% vs its 50-day average ($3.77) and -87.2% vs its 200-day average ($24.98).
- 52-week range $2.25–$135.75; today's close sits at 1% of that range, 97.7% below the 52-week high.
Oct 13, 2026 — JUNS jumps 10.5% to $3.36, 3 up days in a row
- Closed at $3.36, +10.53% vs the prior close of $3.04. Day range $3.00–$3.50, opened at $3.00.
- Volume was 71.30K shares, 0.1x its 50-day average of 1.15M — lighter than usual.
- Price is -13.0% vs its 50-day average ($3.86) and -86.8% vs its 200-day average ($25.39).
- 52-week range $2.25–$135.75; today's close sits at 1% of that range, 97.5% below the 52-week high.
- That makes 3 straight gains.
Oct 12, 2026 — JUNS jumps 6.7% to $3.04
- Closed at $3.04, +6.67% vs the prior close of $2.85. Day range $2.76–$3.04, opened at $2.89.
- Volume was 37.20K shares, 0.0x its 50-day average of 1.15M — lighter than usual.
- Price is -22.9% vs its 50-day average ($3.94) and -88.2% vs its 200-day average ($25.79).
- 52-week range $2.25–$135.75; today's close sits at 1% of that range, 97.8% below the 52-week high.
Oct 9, 2026 — JUNS rises 2.9% to $2.85
- Closed at $2.85, +2.89% vs the prior close of $2.77. Day range $2.67–$2.89, opened at $2.83.
- Volume was 7.00K shares, 0.0x its 50-day average of 1.15M — lighter than usual.
- Price is -29.1% vs its 50-day average ($4.02) and -89.1% vs its 200-day average ($26.17).
- 52-week range $2.25–$135.75; today's close sits at 0% of that range, 97.9% below the 52-week high.
Oct 8, 2026 — JUNS dips 2.5% to $2.77
- Closed at $2.77, -2.46% vs the prior close of $2.84. Day range $2.66–$2.85, opened at $2.70.
- Volume was 36.80K shares, 0.0x its 50-day average of 1.15M — lighter than usual.
- Price is -32.6% vs its 50-day average ($4.11) and -89.6% vs its 200-day average ($26.57).
- 52-week range $2.25–$135.75; today's close sits at 0% of that range, 98.0% below the 52-week high.
Oct 7, 2026 — JUNS dips 0.7% to $2.84
- Closed at $2.84, -0.70% vs the prior close of $2.86. Day range $2.58–$2.86, opened at $2.61.
- Volume was 47.10K shares, 0.0x its 50-day average of 1.15M — lighter than usual.
- Price is -32.4% vs its 50-day average ($4.20) and -89.5% vs its 200-day average ($26.97).
- 52-week range $2.25–$135.75; today's close sits at 0% of that range, 97.9% below the 52-week high.
Oct 6, 2026 — JUNS jumps 18.2% to $2.86
- Closed at $2.86, +18.18% vs the prior close of $2.42. Day range $2.25–$3.18, opened at $2.38.
- Volume was 924.10K shares, 0.8x its 50-day average of 1.13M.
- Price is -33.6% vs its 50-day average ($4.31) and -89.6% vs its 200-day average ($27.38).
- 52-week range $2.25–$135.75; today's close sits at 0% of that range, 97.9% below the 52-week high.
Oct 5, 2026 — JUNS slides 5.1% to $2.42, a 52-week low
- Closed at $2.42, -5.10% vs the prior close of $2.55. Day range $2.33–$2.55, opened at $2.42.
- Volume was 14.90K shares, 0.0x its 50-day average of 1.14M — lighter than usual.
- Price is -45.3% vs its 50-day average ($4.42) and -91.3% vs its 200-day average ($27.79).
- 52-week range $2.33–$135.75; today's close sits at 0% of that range, 98.2% below the 52-week high.
Oct 2, 2026 — JUNS rises 2.0% to $2.55
- Closed at $2.55, +2.00% vs the prior close of $2.50. Day range $2.50–$2.60, opened at $2.50.
- Volume was 11.60K shares, 0.0x its 50-day average of 1.14M — lighter than usual.
- Price is -44.0% vs its 50-day average ($4.56) and -91.0% vs its 200-day average ($28.21).
- 52-week range $2.35–$135.75; today's close sits at 0% of that range, 98.1% below the 52-week high.
JUNS latest news & SEC filings
Every SEC filing by or about JUNS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Sep 25, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 22, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
Aug 28, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 28, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.01 — Stock exchange listing notice or transfer of listing.
- Item 8.01 — Reported other events the company considers important.
Aug 27, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 8.01 — Reported other events the company considers important.
Aug 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 8.01 — Reported other events the company considers important.
Aug 24, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $24.25K
- Net income: -$2.27M (prior year -$2.25M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$4.08 (prior year -$5.09) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.03 — Change to shareholder rights.
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 8.01 — Reported other events the company considers important.
Aug 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade JUNS
- How much it moves: over the last 20 sessions the average daily move was 4.71% (largest 18.2%). That is a volatile stock.
- Liquidity: about 95.38K shares (≈$277.07K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $2.90 vs a range of $2.25–$135.75 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:75 on Aug 7, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Sep 3, 2026; 8-K Aug 28, 2026; 8-K Aug 27, 2026.
- Share count: 770.08K shares outstanding (Aug 14, 2026), -97.8% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
JUNS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 3.09 | 3.10 | 2.88 | 2.90 | 13.92K |
| Oct 15, 2026 | 3.16 | 3.27 | 3.03 | 3.14 | 19.80K |
| Oct 14, 2026 | 3.30 | 3.43 | 3.07 | 3.19 | 20.10K |
| Oct 13, 2026 | 3.00 | 3.50 | 3.00 | 3.36 | 71.30K |
| Oct 12, 2026 | 2.89 | 3.04 | 2.76 | 3.04 | 37.20K |
| Oct 9, 2026 | 2.83 | 2.89 | 2.67 | 2.85 | 7.00K |
| Oct 8, 2026 | 2.70 | 2.85 | 2.66 | 2.77 | 36.80K |
| Oct 7, 2026 | 2.61 | 2.86 | 2.58 | 2.84 | 47.10K |
| Oct 6, 2026 | 2.38 | 3.18 | 2.25 | 2.86 | 924.10K |
| Oct 5, 2026 | 2.42 | 2.55 | 2.33 | 2.42 | 14.90K |
| Oct 2, 2026 | 2.50 | 2.60 | 2.50 | 2.55 | 11.60K |
| Oct 1, 2026 | 2.57 | 2.57 | 2.39 | 2.50 | 13.30K |
| Sep 30, 2026 | 2.51 | 2.61 | 2.35 | 2.44 | 16.80K |
| Sep 29, 2026 | 2.54 | 2.60 | 2.38 | 2.58 | 14.90K |
| Sep 28, 2026 | 2.67 | 2.67 | 2.40 | 2.51 | 53.00K |
| Sep 25, 2026 | 2.82 | 2.97 | 2.67 | 2.67 | 58.90K |
| Sep 24, 2026 | 3.06 | 3.06 | 2.80 | 2.88 | 36.80K |
| Sep 23, 2026 | 2.97 | 3.00 | 2.90 | 2.97 | 37.20K |
| Sep 22, 2026 | 2.90 | 3.68 | 2.86 | 2.98 | 455.70K |
| Sep 21, 2026 | 2.96 | 2.96 | 2.86 | 2.87 | 17.10K |
About Jupiter Neurosciences
Jupiter Neurosciences (JUNS) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in JUPITER, FL. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1679628.
JUNS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Allison W Brady | Director | Jun 5, 2026 |
| Andrew Jon Cutler | Director | Aug 5, 2026 |
| Marshall A. Hayward | Chief Scientific Officer | Jul 13, 2026 |
| Nicholas H. Hemmerly | Director | Jul 13, 2026 |
| Julie B. Kampf | Director | Jul 13, 2026 |
| Tomas Jan Philipson | Director | Jul 1, 2026 |
| Christer Rosen | CEO and Chairman | Jun 4, 2026 |
| Alison D. Silva | President and COO | Jun 4, 2026 |
| Holger Weis | Director | Jul 13, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Saleem Elmasri | Chief Financial Officer | Jun 4, 2026 |
| Marshall A. Hayward | Chief Scientific Officer | Jul 13, 2026 |
| Christer Rosen | CEO and Chairman | Jun 4, 2026 |
| Alexander Gustaf Erik Rosen | Chief Administrative Officer | Jul 13, 2026 |
| Alison D. Silva | President and COO | Jun 4, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
JUNS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $21.80K | $-8.64M | -0.25 | $-5.41M |
| Dec 31, 2024 | — | $-2.44M | -0.08 | $-3.91M |
| Dec 31, 2023 | — | $-4.78M | -0.18 | $-480.95K |
Latest balance sheet: total assets $3.72M, total liabilities $4.08M, cash $— (as of Jun 30, 2026).
JUNS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on JUNS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.